Sulfaphenazole
Sulfabid (sulfaphenazole) is a small molecule pharmaceutical. Sulfaphenazole was first approved as Sulfabid on 1982-01-01. It is known to target cytochrome P450 2C9.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sulfaphenazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULFABID | Pharmaceutical Research Associates Inc | N-013093 DISCN | 1982-01-01 | 1 products |
| SULFABID | Purdue Pharma | N-013092 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
No data
Drug
General
| Drug common name | Sulfaphenazole |
| INN | sulfaphenazole |
| Description | Sulfaphenazole is a sulfonamide that is sulfanilamide in which the sulfonamide nitrogen is substituted by a 1-phenyl-1H-pyrazol-5-yl group. It is a selective inhibitor of cytochrome P450 (CYP) 2C9 isozyme, and antibacterial agent. It has a role as an antibacterial drug, an EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor, an EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor and a P450 inhibitor. It is a substituted aniline, a sulfonamide, a member of pyrazoles, a primary amino compound and a sulfonamide antibiotic. |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 526-08-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1109 |
| ChEBI ID | 77780 |
| PubChem CID | 5335 |
| DrugBank | DB06729 |
| UNII ID | 0J8L4V3F81 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP2C9
CYP2C9
Organism
Homo sapiens
Gene name
CYP2C9
Gene synonyms
CYP2C10
NCBI Gene ID
Protein name
cytochrome P450 2C9
Protein synonyms
(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, Cholesterol 25-hydroxylase, CYPIIC9, cytochrome P-450 S-mephenytoin 4-hydroxylase, Cytochrome P-450MP, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, cytochrome P450, family 2, subfamily C, polypeptide 9, flavoprotein-linked monooxygenase, microsomal monooxygenase, S-mephenytoin 4-hydroxylase, xenobiotic monooxygenase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,109 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use